Lowering adalimumab dose for chronic uveitis
Treatments studied
Part of Eyes & vision clinical trials.
This trial tests whether people with chronic uveitis (eye inflammation) who have been stable on adalimumab (a biologic medicine) for at least 24 weeks can safely reduce their dose. The goal is to see if a lower dose can still control the inflammation while reducing side effects and costs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have chronic non-infectious uveitis (eye inflammation not caused by an infection).
- Your eye inflammation has been fully controlled for at least 48 weeks (or 96 weeks if related to Behçet's disease).
- You have been on adalimumab 40 mg every 2 weeks for at least 24 weeks.
- You have not taken oral steroids for at least 12 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two forms of the same medicine (adalimumab) to treat non-infectious uveitis, an inflammation inside the eye. It aims to see which delivery method works better to control active inflammation and protect vision.
This study tests a drug called adalimumab, which helps calm the immune system, when added to the steroid medicine you may already be taking. It aims to see if this combination is safe and works better for people with Behçet's disease that affects the back of the eye and has recently flared up.
This trial tests whether minocycline, an antibiotic that can also reduce inflammation, helps improve chronic autoimmune uveitis and protect vision. It may help by lowering ongoing immune irritation that damages the eye.
This study tests a new drug (GenSci048) for people with active, non-infectious uveitis in the middle or back of the eye, who are already taking oral steroids. The goal is to see if the drug can better control inflammation and reduce the need for steroids.
This study tests if checking the amount of adalimumab (a biologic drug) in your blood can help doctors safely lower your dose. If you have had rheumatoid arthritis under control for at least 6 months, this trial may help you take less medication while keeping symptoms away.
This study tests whether adjusting the dose of adalimumab (a medicine that helps control inflammation) can keep eye inflammation and joint symptoms under control in children and young adults with JIA or chronic anterior uveitis. If you have been stable on adalimumab for a long time, this trial may help find the best dose for you.
Hear when a new Uveitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.